|
|
|
| The Application Value of Metallothionein-3 Combined with Tumor Markers in the Evaluation of Postoperative Efficacy of TACE for Primary Liver Cancer |
| ZHANG Lijing, WANG Pei |
| Department of Digestive Endocrinology, The Fourth People's Hospital of Shaanxi, Xi'an Shaanxi 710043 |
|
|
|
|
Abstract 【Objective】To explore the application value of metallothionein-3 (MT-3) combined with tumor markers in evaluating the postoperative efficacy of transcatheter arterial chemoembolization (TACE) for primary liver cancer.【Methods】A retrospective analysis was conducted on the clinical data of 80 TACE treated primary liver cancer patients admitted to the Fourth People's Hospital of Shaanxi Province from January 2019 to January 2022. They were divided into a control group and an uncontrolled group based on their clinical efficacy. Clinical data such as Age,gender,body mass index (BMI),Child Pugh grading of liver function,tumor site,number of tumors,degree of tumor cell differentiation,tumor type,serum total bilirubin (TBIL),and serum tumor markers [CYFRA21-1,Squamous cell carcinoma antigen (SCC),carcinoembryonic antigen (CEA),alpha fetoprotein (AFP),carbohydrate antigen 19-9 (CA19-9)],and serum MT-3 of two groups of patients were collected; The evaluation value of serum MT-3 combined with tumor markers in the postoperative efficacy of TACE in patients with primary liver cancer were analyzed using the receiver operating characteristic (ROC) curve.【Results】Among the 80 cases,65 patients(81.25%) were effectively treated and included in the control group;15 patients (18.75%) were included in the uncontrolled group due to ineffective treatment. There was no statistically significant difference (P>0.05) between the two groups in terms of gender,tumor diameter,number of tumors,tumor location,degree of tumor cell differentiation,tumor type,liver cirrhosis,proportion of Child Pugh grading of liver function,age,BMI,TBIL,CA19-9,CEA; The levels of CYFRA21-1,SCC,and AFP in the uncontrolled group were higher than those in the control group (P<0.05),while the levels of MT-3 were lower than those in the control group (P<0.05). The ROC curve analysis results show that CYFRA21-1,SCC,AFP,and MT-3 all have certain predictive value for the postoperative efficacy of TACE in patients with primary liver cancer.【Conclusions】CYFRA21-1,SCC,AFP,and MT-3 have certain predictive value for the postoperative efficacy of TACE in patients with primary liver cancer,and the combined predictive value is higher. Clinicians should pay close attention to them.
|
|
Received: 23 November 2022
|
|
|
|
|
|
[1] 郭飞宇,杨军,熊书名,等. 表皮生长因子受体和胸苷酸合成酶在原发性肝癌中的表达和意义[J].中华肝脏病杂志,2018,26(9):666-669.
[2] 陈林林,王花花,王娅菲,等. TACE联合索拉非尼对原发性肝癌的疗效及其预后相关影响因素[J].肝脏,2019,24(5):571-573.
[3] 王颖栋,丁海斌,黄子超,等.华蟾素联合仑伐替尼治疗经动脉化疗栓塞术后原发性肝癌患者的近期疗效[J].医学临床研究,2022,39(1):9-12.
[4] 胡媛媛,肖红兵,孙东旭,等. 经导管动脉化疗栓塞联合微波消融治疗中晚期肝癌的远期疗效及影响因素研究[J].实用癌症杂志,2015,30(5):704-707.
[5] 尹晓东,后博,李海洋,等. 中晚期原发性肝癌患者TACE术后VEGFR表达水平与疗效的相关性分析[J].肝脏,2021,26(10):1107-1111.
[6] 王昊,林飞,郭晓光,等. 金属硫蛋白-3和P73蛋白在食管鳞癌组织中的表达及意义[J].中华临床医师杂志(电子版),2014,8(18):3225-3231.
[7] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作委员会,中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3):259-269.
[8] 杨学宁,吴一龙. 实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[9] 许洲松,方大鹏,陈中平. 血清CYFRA21-1等肿瘤标志物预测肝癌TACE序贯索拉非尼治疗疗效的临床价值[J].现代医药卫生,2019,35(15):2308-2312.
[10] 杨秋雨,魏宁,徐浩,等. TACE联合卡瑞利珠单抗治疗中晚期肝癌短期疗效及疗效相关性分析[J].医学影像学杂志,2021,31(7):1212-1219.
[11] SONG X M,WANG Z J,CAO W J,et al. The value of circulating CYFRA21-1 expression in patients with nasopharyngeal carcinoma: a study of 529 subjects[J].Int J Clin Oncol,2016,21(6):1038-1045.
[12] 王斐斐,柳仲秋,贺启华,等. 84例原发性肝癌患者肝动脉化疗栓塞术后预后的影响因素分析[J].癌症进展,2017,15(1):85-93.
[13] 刘占钰,钟莹,江丽霞,等.联合检测血清AFP、CA50以及CYFRA21-1对原发性肝癌的诊断价值[J].解放军预防医学杂志,2019,37(3):33-34.
[14] 潘隽永,王高雄,欧阳家和,等. 金属硫蛋白-1G对肝癌细胞增殖的影响[J].中华实验外科杂志,2020,37(3):461-464.
[15] 王瑜,俞乔. 浸润性导管型乳腺癌中金属硫蛋白3的表达及意义[J].肿瘤学杂志,2020,26(1):39-42.
[16] 吴军,闫雪华,陈小勇,等. 金属硫蛋白-3与肝细胞肝癌TACE治疗近、远期疗效的关系[J].介入放射学杂志,2021,30(2):168-172. |
|
|
|
2023, Vol. 40 
